share_log

Cantor Fitzgerald Reiterates Overweight on Novo Nordisk, Maintains $160 Price Target

Benzinga ·  Oct 10 23:19  · Ratings

Cantor Fitzgerald analyst Louise Chen reiterates Novo Nordisk (NYSE:NVO) with a Overweight and maintains $160 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment